HUE036378T2 - Humán embrionális õssejtek felhasználási módszerei a gyógyászatban alkalmazott vegyületek és egyéb vegyszerek toxicitásának értékelésére - Google Patents

Humán embrionális õssejtek felhasználási módszerei a gyógyászatban alkalmazott vegyületek és egyéb vegyszerek toxicitásának értékelésére

Info

Publication number
HUE036378T2
HUE036378T2 HUE07755255A HUE07755255A HUE036378T2 HU E036378 T2 HUE036378 T2 HU E036378T2 HU E07755255 A HUE07755255 A HU E07755255A HU E07755255 A HUE07755255 A HU E07755255A HU E036378 T2 HUE036378 T2 HU E036378T2
Authority
HU
Hungary
Prior art keywords
chemicals
methods
stem cells
embryonic stem
human embryonic
Prior art date
Application number
HUE07755255A
Other languages
English (en)
Inventor
Gabriela Cezar
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of HUE036378T2 publication Critical patent/HUE036378T2/hu

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
HUE07755255A 2006-04-10 2007-04-10 Humán embrionális õssejtek felhasználási módszerei a gyógyászatban alkalmazott vegyületek és egyéb vegyszerek toxicitásának értékelésére HUE036378T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79064706P 2006-04-10 2006-04-10
US82216306P 2006-08-11 2006-08-11

Publications (1)

Publication Number Publication Date
HUE036378T2 true HUE036378T2 (hu) 2018-07-30

Family

ID=38515874

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE07755255A HUE036378T2 (hu) 2006-04-10 2007-04-10 Humán embrionális õssejtek felhasználási módszerei a gyógyászatban alkalmazott vegyületek és egyéb vegyszerek toxicitásának értékelésére

Country Status (11)

Country Link
US (2) US8703483B2 (hu)
EP (1) EP2013619B1 (hu)
JP (2) JP5421767B2 (hu)
BR (1) BRPI0710054B8 (hu)
CA (1) CA2648218C (hu)
DK (1) DK2013619T3 (hu)
GB (1) GB2451042A (hu)
HU (1) HUE036378T2 (hu)
MX (1) MX2008013002A (hu)
SE (2) SE1050445A1 (hu)
WO (1) WO2007120699A2 (hu)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008040532A1 (en) * 2006-10-02 2008-04-10 Cellartis Ab Novel toxicity assay based on human blastocyst-derived stem cells and progenitor cells
WO2008097491A2 (en) * 2007-02-05 2008-08-14 Wisconsin Alumni Research Foundation Biomarkers of ionizing radiation response
US7964843B2 (en) 2008-07-18 2011-06-21 The George Washington University Three-dimensional molecular imaging by infrared laser ablation electrospray ionization mass spectrometry
US20100285446A1 (en) * 2007-07-20 2010-11-11 Akos Vertes Methods for Detecting Metabolic States by Laser Ablation Electrospray Ionization Mass Spectrometry
US8901487B2 (en) * 2007-07-20 2014-12-02 George Washington University Subcellular analysis by laser ablation electrospray ionization mass spectrometry
US8067730B2 (en) 2007-07-20 2011-11-29 The George Washington University Laser ablation electrospray ionization (LAESI) for atmospheric pressure, In vivo, and imaging mass spectrometry
WO2010030293A1 (en) * 2008-09-15 2010-03-18 Gentron, Inc. Methods, systems, and compositions for cancer diagnosis
CN102414309A (zh) * 2009-03-10 2012-04-11 拜耳医药保健有限公司 用于监测细胞培养物的方法
GB0911060D0 (en) 2009-06-26 2009-08-12 Ge Healthcare Uk Ltd Methods for predicting the toxicity of a chemical
EP2486404B1 (en) * 2009-10-06 2018-08-15 Wisconsin Alumni Research Foundation Metabolic biomarkers of drug-induced cardiotoxicity
EP2491508A2 (de) * 2009-10-21 2012-08-29 BASF Plant Science Company GmbH Verfahren zur erzeugung von biomarker-referenzpattern
JP5814337B2 (ja) * 2010-03-22 2015-11-17 ステミナ バイオマーカー ディスカバリー， インコーポレイテッド ヒト幹細胞様細胞及びメタボロミクスを使用した医薬のヒト発生毒性の予測
WO2011139914A1 (en) * 2010-04-29 2011-11-10 Wisconsin Alumni Research Foundation Metabolic biomarkers of autism
US8945847B2 (en) 2010-05-24 2015-02-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and kits for ascertaining biosafety of an agent
WO2012068170A2 (en) 2010-11-15 2012-05-24 Jau-Nan Lee Generation of neural stem cells from human trophoblast stem cells
US8829426B2 (en) 2011-07-14 2014-09-09 The George Washington University Plume collimation for laser ablation electrospray ionization mass spectrometry
US9164106B2 (en) * 2012-03-15 2015-10-20 Greenwood Genetic Center, Inc. Determination of decreased metabolism of tryptophan in diagnosis of autism spectrum disorders
HUE043604T2 (hu) 2012-11-02 2019-08-28 Stemina Biomarker Discovery Inc Gyógyszerek humán fejlõdési toxicitásának elõrejelzésére humán õsjellegû sejtek és metabolomikus arányok alkalmazásával
CN113604423B (zh) 2012-11-30 2025-06-03 艾克塞利瑞提德生物技术公司 通过调节mir-124分化干细胞的方法
CA2916520A1 (en) * 2013-07-03 2015-01-08 Coyne Ip Holdings, Llc Methods for predicting responses to chemical or biologic substances
SG10202009095VA (en) 2014-11-26 2020-10-29 Accelerated Biosciences Corp Induced hepatocytes and uses thereof
GB201519186D0 (en) * 2015-10-30 2015-12-16 Electrophoretics Ltd Isotopic methods for measurement of tryptophan and metabolites thereof
WO2018157004A1 (en) * 2017-02-24 2018-08-30 Coyne Scientific, Llc Methods for determining the incidence and/or intensity of effects of a chemical or biological agent on members of a target population using stem cells
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
KR102083408B1 (ko) * 2017-04-28 2020-03-02 가천대학교 산학협력단 줄기세포 기반의 독성 물질 스크리닝 방법
WO2020232436A1 (en) 2019-05-16 2020-11-19 Brown University A human in vitro cardiotoxicity model
WO2021203014A1 (en) 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated Pyrano[4,3-b]l ndole derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)
EP4126819A1 (en) * 2020-04-03 2023-02-08 Vertex Pharmaceuticals Incorporated 7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)
US12504423B2 (en) 2020-10-16 2025-12-23 Brown University Human in vitro cardiotoxicity model
US12076437B2 (en) 2021-07-12 2024-09-03 Brown University Proangiogenic protein cocktails delivered in custom biomaterials to revascularize ischemic tissue
US20250246259A1 (en) 2022-03-30 2025-07-31 Infinite D.O.O. Method for predictive testing of agents to assess triggering and suppressing adverse outcomes and/or diseases
CN121136913B (zh) * 2025-11-17 2026-04-03 杭州艾名医学科技有限公司 一种肠类器官模型体外评价药物肠毒性的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
JPH11225795A (ja) 1998-02-13 1999-08-24 Oriental Yeast Co Ltd 細胞障害マーカー
WO1999047922A2 (en) * 1998-03-18 1999-09-23 Massachusetts Institute Of Technology Vascularized perfused microtissue/micro-organ arrays
AU2001266650A1 (en) 2000-06-02 2001-12-17 Large Scale Proteomics Corp Protein markers for pharmaceuticals and related toxicity
US6680203B2 (en) 2000-07-10 2004-01-20 Esperion Therapeutics, Inc. Fourier transform mass spectrometry of complex biological samples
EP1176189A1 (en) 2000-07-21 2002-01-30 Fornix Biosciences N.V. Stem cell-like cells
WO2002066635A1 (en) * 2001-02-23 2002-08-29 Gencom Corporation Transgenic animal having drug metabolism enzyme gene and utilization thereof
EP1417629B1 (en) 2001-07-06 2008-02-20 Lipomics Technologies, Inc. Generating, viewing, interpreting, and utilizing a quantitative database of metabolites
CA2458575C (en) 2001-08-24 2014-07-08 Advanced Cell Technology, Inc. Screening assays for identifying differentiation-inducing agents and production of differentiated cells for cell therapy
US20030232430A1 (en) * 2001-11-26 2003-12-18 Advanced Cell Technology Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
US6982152B2 (en) * 2002-04-17 2006-01-03 Promega Corporation Cytotoxicity assay
US20040121305A1 (en) 2002-12-18 2004-06-24 Wiegand Roger Charles Generation of efficacy, toxicity and disease signatures and methods of use thereof
EP1589814B1 (en) * 2003-01-16 2009-08-12 The General Hospital Corporation Use of three-dimensional microfabricated tissue engineered systems for pharmacologic applications
JP2005022096A (ja) 2003-06-30 2005-01-27 Three M Innovative Properties Co 遮光性装飾シート
EP1644485B9 (en) * 2003-07-08 2012-01-04 Axiogenesis Ag Secreted proteins as markers for cell differentiation
AU2004256209B2 (en) * 2003-07-08 2010-04-08 Axiogenesis Ag Novel method for the preparation of embryoid bodies (EBs) and uses thereof
US20070298453A1 (en) 2004-02-12 2007-12-27 University Of Newcastle Upon Tyne Stem Cells
DK1740945T3 (en) 2004-04-07 2019-01-21 Ncardia Ag KKE-INVASIVE, IN-VITRO FUNCTIONAL TISSUE TEST SYSTEMS

Also Published As

Publication number Publication date
JP2009533056A (ja) 2009-09-17
GB2451042A (en) 2009-01-14
US8703483B2 (en) 2014-04-22
GB0820454D0 (en) 2008-12-17
BRPI0710054B1 (pt) 2020-11-17
WO2007120699A2 (en) 2007-10-25
MX2008013002A (es) 2008-10-17
DK2013619T3 (en) 2017-12-04
EP2013619A2 (en) 2009-01-14
US20140255969A1 (en) 2014-09-11
SE1050445A1 (sv) 2010-05-04
JP2013078342A (ja) 2013-05-02
SE0850071L (sv) 2008-12-19
WO2007120699A3 (en) 2008-01-24
US20070248947A1 (en) 2007-10-25
JP5421767B2 (ja) 2014-02-19
BRPI0710054A2 (pt) 2011-08-02
EP2013619B1 (en) 2017-10-11
CA2648218A1 (en) 2007-10-25
BRPI0710054B8 (pt) 2021-07-27
CA2648218C (en) 2015-06-02

Similar Documents

Publication Publication Date Title
HUE036378T2 (hu) Humán embrionális õssejtek felhasználási módszerei a gyógyászatban alkalmazott vegyületek és egyéb vegyszerek toxicitásának értékelésére
GB2441718B (en) Differentiation of human embryonic stem cells to cardiomyocyte-lineage cells
ZA200804454B (en) Use of pyrroloquinoline compounds to kill clinically latent microorganisms
IL193702A0 (en) A pharmaceutical composition containing human embryonic stem cells
ZA201001158B (en) Diferentiation of human embryonic stem cells
IL194958A0 (en) Use of arylcarboxylic acid biphenylamides for seed treatment
EP2117523A4 (en) HAMMER OF ACT ACTIVITY
EP2210608A4 (en) PHARMACEUTICAL COMPOSITION WITH HUMAN MESENCHYM STEM CELLS
EP2484359A4 (en) HEPARANASEAKTIVITÄTSHEMMER
EP2413932A4 (en) HAMMER OF ACT ACTIVITY
ZA200900392B (en) Biological production of fuels
EP2406250A4 (en) HAMMER OF ACT ACTIVITY
EP2299825A4 (en) HAMMER OF ACT ACTIVITY
IL189614A0 (en) Pharmaceutical compositions of telmisartan
ZA200801471B (en) Process for the hydrogenation of glycerol to propyleneglycol
PT1850664E (pt) Formulação de cápsulas
IL197297A0 (en) Azabicyclic compounds as inhibitors of monoamines reuptake
EP1938842A4 (en) METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION COMPRISING IMPROVED CRASHING CHARACTERISTICS
EP2405756A4 (en) HAMMER OF ACT ACTIVITY
IL212057A0 (en) Compositions for the treatment of bowel diseases with granulated mesalamine
EP2023925A4 (en) CDKI PATH HEMMER AS SELECTIVE TEMPORARY GROWTH INHIBITORS
PT2409698E (pt) Utilização de um ácido indazol-metoxialcanóico para a preparação de uma composição farmacêutica
IL193687A0 (en) Formulations of sitaxsentan sodium
EP1919688A4 (en) PROCESS FOR THE APPLICATION OF INGREDIENTS WITHIN A STRAW
GB0624963D0 (en) Derivatives of 188-Glycyrrhetinic Acid